65,437 trials
Chronic Myeloid Leukemia · Philadelphia-Positive Myeloid Leukemia
Primary: Number of Participants With Major Cytogenetic Response (MCyR) at Week 12 — 36; 14 Participants
Aspergillosis
Primary: Number of Subjects With Successful Global Outcome at 6 Months: Chronic Bronchopulmonary Aspergillosis — 13; 28 participants
Gastroesophageal Reflux
Primary: Number of Patients Withdrawn From Study Due to Lack of Efficacy. — 6; 6 patients — p=1.0
Crohn's Disease
Primary: Percentage of Subjects Achieving Clinical Remission — 69.5 Percentage of participants
Pulmonary Disease, Chronic Obstructive
Primary: Number of Participants With a Post-bronchodilator FEV1/FVC <=70% Versus Participants With a Postbronchodilator FEV1/FVC >70% — 308; 893 participants
Bacterial Vaginosis
Primary: Recurrent Bacterial Vaginosis — 7; 7 Participants — p=0.75
Non-Small-Cell Lung Cancer
Primary: Percentage of Participants Surviving Progression-Free at 6 Months (Progression Free Survival [PFS] Rate) — 52.8; 39.3 percentage
Gastroesophageal Reflux
Primary: Number of Patients With Laboratory Test Values of Potential Clinical Importance During Treatment Period — 0; 3; 0; 1 patients
HIV Infections
Primary: Percentage of Participants With HIV-1 RNA <50 Copies/mL (c/mL) Through Week 48 of the Maintenance Phase — 78; 75 Percentage of participants
Renal Transplant
Primary: Number of Patients Experiencing Biopsy Confirmed Acute Rejection Through Month 6 After Transplantation. — 12 patients
Diabetes · Diabetes Mellitus, Type 2
Primary: Glycosylated Haemoglobin A1c (HbA1c) — 7.08; 7.23 percentage of total haemoglobin — p=0.029
Hepatitis B · Chronic Disease
Primary: Change From Baseline in Hepatitis B Virus DNA (HBV DNA) by Polymerase Chain Reaction (PCR) Assay at Week 12 — -6.23; -4.52 log10 copies/mL
Dyslipidemia
Primary: Plasma Area Under the Curve (AUC(0 to 48hr)) for Simvastatin Acid — 9.19; 8.03 ng/mL * Hour
Perennial Allergic Rhinitis
Primary: Allergic Rhinitis Symptom Score Including Rhinorrhea, Nasal Obstruction, Sneezing, Itchy Nose and Itchy Eyes at Week 4 — 2.82; 2.8; 1.19; 1.21 Unit Score
Attention Deficit Disorder With Hyperactivity
Primary: Change From Baseline to 12 Week Endpoint in Child Health and Illness Profile - Child Edition (CHIP-CE), Achievement Domain — 2.65; 0.51; 3.89 T-Score